Navigation Links
Harvard University: Big Pharma is Corrupted; CBCD Sees Connection between Corruption & Productivity Crisis in R&D
Date:11/1/2013

Rochester, NY (PRWEB) November 01, 2013

Big Pharma suffers from institutional corruption according to Harvard University researchers (1). They came to this conclusion after examining Pharma’s practices and policies in 5 different categories: systemic problems, medical research, medical knowledge and practice, marketing, and patient advocacy organizations. The CBCD believes this institutional corruption is a result of the productivity crisis in pharmaceutical R&D.

What is institutional corruption?

According to Marc A. Rodwin, one of the lead researchers, institutional corruption is “widespread or systemic practices, usually legal, that undermine an institution's objectives or integrity. Institutional corruption displaces some goals and compromises the attainment of others (2).”

An example of systemic corruption, (corruption of the entire system, or way of doing things) is Big Pharma’s funding of political campaigns, selectively providing information to legislators, subsidizing their work, and targeting campaign contributions to influential legislators and allies (1). Another example of a systemic problem is the fact that “Firms have strong financial incentives to develop so-called me-too drugs - products which are minor variations of existing drugs - and to heavily market them in ways that exaggerate their benefits and fail to reveal their full risks (1).”

The Harvard researchers found that Big Pharma manipulates physicians across America to achieve their financial goals. They wrote that “widespread practices in the medical and pharmaceutical industries can lead to doctors who are psychologically, financially, or intellectually dependent on drug companies (1).” In other words, Pharma turned these doctors into their agents. This is a phenomenon which has “resulted in…Doctors who take such misleading information at face value (and) prescribe drugs that are often unnecessary, harmful to patients, or more costly than equivalent medications (1).”

In short, the Harvard researchers “uncovered how pharmaceutical marketing …distorts medical practice… (1).”

When normal people become corrupted, it is usually due to extreme pressure. For example, when someone holds a gun to the head of one’s child, or when one is bankrupt and must still purchase food for one’s family…then one may be driven to extreme acts. The same holds true for Big Pharma. The productivity crisis is driving Pharma to extreme measures. These extreme measures were labeled by researchers as ‘institutional corruption.’

For more information on the productivity crisis in pharmaceutical R&D, please visit:

http://www.prweb.com/releases/2013/10/prweb11232090.htm

and

http://www.prweb.com/releases/2013/10/prweb11273236.htm

The CBCD invites pharmaceutical executives to contact the Center to discuss forward thinking strategies that can help reduce corruption while maximizing profits.

We invite the media to contact us for interviews at: info (at)buy-gene-eden(dot)com or phone 585-250-9999.

###

References:
(1)    http://www.law.harvard.edu/news/2013/10/25_edmond-j-safra-center-for-ethics-fellows-jlme.html
(2)    http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2298140
(3)    http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101

The Center for the Biology of Chronic Disease (CBCD, http://www.cbcd.net) is a research center recognized by the IRS as a 501(c)(3) non-for-profit organization. The mission of the CBCD is to advance the research on the biology of chronic diseases, and to accelerate the discovery of treatments.

The CBCD published the “Purple” book by Dr. Hanan Polansky. The book presents Dr. Polansky’s highly acclaimed scientific theory on the relationship between foreign DNA and the onset of chronic diseases. Dr. Polansky’s book is available as a free download from the CBCD website.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11290033.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Harvard researchers, pharma experts offer recommendations to expand access to clinical trial data
2. Genia Technologies, Columbia University, and Harvard University Awarded $5.25 Million Grant from NIH to Accelerate the Development of NanoTag DNA Sequencing Technology
3. Jeffrey Epstein, Science Financier, Changes the Course of Evolution at Harvard
4. Director of Proteomics at the Broad Institute of MIT and Harvard, Steven Carr, to Deliver Pittcon 2014 Wallace H. Coulter Plenary Lecture
5. Life Technologies Signs License and Collaborative Stem Cell Research Agreement with Harvard University
6. Harvard Wyss Institutes Lung-on-a-Chip wins prize for potentially reducing need for animal testing
7. Harvards Wyss Institute team creates versatile 3d nanostructures using DNA bricks
8. Harvards Wyss Institute models a human disease in an organ-on-a-chip
9. UMass Amherst, Harvard experts say better systems needed for medical device cybersecurity
10. Harvards Wyss Institute creates living human gut-on-a-chip
11. Harvards Wyss Institute develops DNA nanorobot to trigger targeted therapeutic responses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
Breaking Biology News(10 mins):